slides · global inventory
Show Traction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 11,828
Current window 6,541-6,570
Pages 395
Rows per page 30
Slide function
6,541-6,570 of 11,828
31
Includes survival curves (Kaplan-Meier), tumor imaging, and tumor frequency metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
33
Includes two side-by-side clinical data visualizations (line charts and bar charts) comparing patient outcomes.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
35
The chart is a conceptual visualization of 100% of patients achieving 4 months mPFS.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
41
Includes two sets of charts: tumor volume line graphs and survival curves. References Abouzeid et al. (2013/2014).Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
05
TPD stands for Targeted Protein Degradation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
13
The slide uses a bulleted list structure to categorize findings between healthy volunteers and patients, concluding with a strategic partnership milestone.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
17
The chart demonstrates therapeutic efficacy by showing post-treatment levels (Day 28) dropping below or equal to the healthy subject baseline.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
18
The slide compares cytokine inhibition across three cohorts (MAD3 Healthy Subjects, Part C AD Patients, Part C HS Patients) using two different stimuli (LPS and R848).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
19
The chart specifically visualizes IL-6 reduction over time, while the table summarizes max reduction across four markers.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
21
Data based on N=7 patients. Includes error bars representing standard error or confidence intervals.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
22
The chart tracks patient outcomes over time, showing a shift from severe/moderate to mild categories.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
24
The slide uses a comparison table to highlight efficacy metrics (EASI, Pruritus NRS) across different time points and benchmarks.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
26
Data presented across three line charts comparing 'All HS Patients' vs 'Moderate to Severe' subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
27
The charts demonstrate a shift from higher severity scores (orange/red) to lower severity scores (blue/black) over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
36
The slide presents two charts: a tumor growth inhibition curve and a PK/PD correlation chart showing drug concentration vs. target degradation over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
39
The slide presents longitudinal pharmacodynamic (PD) data for three targets across four dose levels, comparing clinical results to preclinical expectations.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
40
The slide uses a split-layout to contrast clinical data findings with the strategic clinical development plan.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
43
The slide presents two charts: a tumor volume growth curve over time and a PK/PD profile showing drug concentration and target knockdown over 240 hours.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
47
Includes a line chart showing % change over time and a summary table of patient-level degradation data.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
48
Includes bar charts for SAA/CRP, a longitudinal line chart for SOCS3, and a scatter plot showing correlation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
49
Data cut-off date May 1, 2023. DL1-3 completed, DL4 open.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
54
Data presented as tumor volume growth curves and Kaplan-Meier survival plots.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
56
Shows two distinct experiments: DFAM-68555 (leukemia burden) and MOLM-13 (tumor volume).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
11
The chart uses a dual-axis approach to correlate margin expansion with ODR revenue mix shift.Limbach Holdings | Investor Presentation Deck | 26 slides · Limbach
Pitch deck Investor relations 1 hit
20
The slide uses stacked bar charts to break down GCR and ODR segments for Revenue and Gross Profit, and simple bars for Adjusted EBITDA.Limbach Holdings | Investor Presentation Deck | 26 slides · Limbach
Pitch deck Investor relations Beat · Financials1 hit
21
The slide uses stacked bar charts to show segment contribution (GCR vs ODR) and simple bar charts for EBITDA.Limbach Holdings | Investor Presentation Deck | 26 slides · Limbach
Pitch deck Investor relations Beat · Financials1 hit
21
The slide uses stacked bar charts to break down performance by GCR and ODR segments.Limbach Holdings | Investor Presentation Deck | 27 slides · Limbach
Pitch deck Investor relations Beat · Financials1 hit
22
The slide uses stacked bar charts to show segment contributions (GCR vs ODR) and simple bar charts for EBITDA.Limbach Holdings | Investor Presentation Deck | 27 slides · Limbach
Pitch deck Investor relations Beat · Financials1 hit
14
The slide provides a breakdown of vehicle orders (buses vs trucks) and charging station orders, alongside logos of school bus and truck clients.Lion Electric | Investor Presentation Deck | 32 slides · Lion Electric
Pitch deck Investor relations 1 hit
15
Lion Electric | Investor Presentation Deck | 32 slidesLion Electric | Investor Presentation Deck | 32 slides · Lion Electric
Pitch deck Investor relations 1 hit